Astellas Pharma

FDA approves Vyloy for HER2-negative gastric and GEJ cancer

FDA · HER2-negative gastric cancer · 5 min

The FDA approved zolbetuximab-clzb (Vyloy) with chemotherapy for gastric and gastroesophageal junction adenocarcinoma on October 18, 2024. Astellas says it is the first and only CLDN18.2-targeted therapy approved in the U.S. for these cancers.